A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

Tel Aviv University scientists say that they can inject CRISPR genetic 'molecular scissors' to shrink tumors by 90%; ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

Researchers from Tel Aviv University utilized CRISPR to cut a single gene from cancer cells of head and neck tumors—and ...

University of Illinois at Urbana-Champaign researchers have developed a CRISPR-based diagnostic tool capable of detecting ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...